

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1-26. (cancelled)

27. (currently amended) A compound comprising:

- (a) one or more MHC-peptide complexes; and
- (b) an antibody or fragment thereof specific for a cell surface marker selected from the group consisting of a cell surface marker of a professional antigen presenting cell, a cell surface marker of a tumor cell, a cell surface marker of a an epithelial cell, a cell surface marker of a fibroblast, CD28, CTLA-4 and CD25;

wherein said MHC-peptide complexes comprise an MHC class II α chain or fragment thereof, an MHC class II β chain or fragment thereof, and an antigenic peptide bound in the MHC groove; and

wherein at least one chain or fragment thereof of said MHC-peptide complexes are linked to the carboxyl terminus of said antibody or fragment thereof.

28. (original) The compound of claim 27, wherein said cell surface marker is a cell surface marker of a professional antigen presenting cell.

29. (original) The compound of claim 28, wherein said professional antigen presenting cell is a dendritic cell.

30. (original) The compound of claim 29, wherein said cell surface marker is selected from the group consisting of CD83, CMRF-44, CMRF-56 and DEC-205.

31. (original) The compound of claim 27, wherein said cell surface marker is a cell surface marker of a tumor cell.

32. (original) The compound of claim 27, wherein said cell surface marker is a cell surface marker of an epithelial cell.

33. (original) The compound of claim 27, wherein said cell surface marker is a cell surface marker of a fibroblast.

34. (cancelled)

35. (currently amended) The compound of claim 27[[34]], wherein said cell surface marker is selected from the group consisting of CD28, CTLA-4 and CD25.

36. (original) The compound of claim 27, wherein said antigenic peptide is derived from a cancer cell.

37. (original) The compound of claim 27, wherein said antigenic peptide is derived from an infectious agent or from infected cells.

38. (cancelled)

39. (original) The compound of claim 31, wherein said antigenic peptide is derived from a cancer cell.

40-119. (cancelled)

120. (new) A compound comprising:

(a) one or more MHC-peptide complexes; and

(a) an antibody or fragment thereof specific for a cell surface marker;

wherein said MHC-peptide complexes comprise an MHC class II α chain or fragment thereof, an MHC class II β chain or fragment thereof, and an antigenic peptide bound in the MHC groove;

wherein at least one chain or fragment thereof of said MHC-peptide complexes are linked to the carboxyl terminus of said antibody or fragment thereof; and

wherein said antigenic peptide is derived from an agent or cell selected from the group consisting of a cancer cell, an infectious agent or infected cells.

121. (new) The compound of claim 120, wherein said cell surface marker is a cell surface marker of a professional antigen presenting cell.

122. (new) The compound of claim 121, wherein said professional antigen presenting cell is a dendritic cell.
123. (new) The compound of claim 122, wherein said cell surface marker is selected from the group consisting of CD83, CMRF-44, CMRF-56 and DEC-205.
124. (new) The compound of claim 120, wherein said cell surface marker is a cell surface marker of a tumor cell.
125. (new) The compound of claim 120, wherein said cell surface marker is a cell surface marker of an epithelial cell.
126. (new) The compound of claim 120, wherein said cell surface marker is a cell surface marker of a fibroblast.
127. (new) The compound of claim 120, wherein said cell surface marker is selected from the group consisting of CD28, CTLA-4 and CD25.
128. (new) The compound of claim 120, wherein said antigenic peptide is derived from a cancer cell.
129. (new) The compound of claim 120, wherein said antigenic peptide is derived from an infectious agent or from infected cells.

130. (new) The compound of claim 124, wherein said antigenic peptide is derived from a cancer cell.